ArticleCancer medicine2026
Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020-2044: A Population-Based Statistical Modelling Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTRK inhibitors targeting NTRK fusion-positive cancers have the potential to improve patient outcomes, but also have high costs. We report the first long-term projections of cancer prevalence associated with NTRK gene fusions in Australia, to 2044.
methodsWe analysed national Australian Institute of Health and Welfare incidence (1982-2019) and survival (1991-2019), NSW Enduring Cancer Data Linkage incidence (1982-2019) and survival data (1982-2019). We projected 1-year to 5-year cancer prevalence using validated statistical methods, for all stages combined, advanced disease at diagnosis (here, distant metastasis/lymph node involvement), and advanced disease after progression post-diagnosis. We estimated prevalence for all paediatric cancers combined (age < 18 years at diagnosis), all adult solid cancers combined, 18 cancer types/groups, and 5 cancer sub-types relevant to current Australian government subsidies of TRK inhibitors.
resultsFor all solid cancers combined, we project increasing prevalence of individuals who were diagnosed with tumours exhibiting NTRK gene fusions, primarily due to population growth and ageing. For example, for 2-year prevalence (aligning with 2.5 years average treatment assumed in previous economic assessments for a TRK inhibitor subsidy), the projected increases from 2019 to 2044 are: all stages combined, paediatric cancers 80 to 106 (+ 32.5%), adult cancers 645 to 970 (+ 50.4%); advanced disease at diagnosis, paediatric cancers 19 to 23 (+ 21.1%), adult cancers 185 to 261 (+ 41.1%); advanced disease after progression post-diagnosis, paediatric cancers 22 to 30 (+ 36.4%), adult cancers 110 to 180 (+ 63.6%).
conclusionThe results from this study can support healthcare planning and budget forecasts, including for different potential government treatment subsidy scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.